HOB Biotech GroupLtd Full Year 2024 Earnings: EPS: CN¥0.59 (vs CN¥0.75 in FY 2023)

Simply Wall St

February 28, 2025

HOB Biotech GroupLtd (SHSE:688656) Full Year 2024 Results

Key Financial Results

Revenue: CN¥402.3m (up 2.0% from FY 2023).
Net income: CN¥36.8m (down 22% from FY 2023).
Profit margin: 9.2% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses.
EPS: CN¥0.59 (down from CN¥0.75 in FY 2023).

earnings-and-revenue-history — SHSE:688656 Earnings and Revenue History February 28th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

HOB Biotech GroupLtd shares are up 6.2% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for HOB Biotech GroupLtd (1 makes us a bit uncomfortable!) that you need to be mindful of.

If you're looking to trade HOB Biotech GroupLtd, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if HOB Biotech GroupLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.